Our calculations also showed that FPRX isn't among the 30 most popular. Tyler Hubbard of Florida Georgia Line sings to the crowd at the Iowa State Fair Grandstand in 2018. UpdatedApril 21, 2020. Those materials and all other documents filed by, or caused to be filed by, Amgen and Purchaser and Five Prime with the SEC will be available at no charge on the SEC's website at www.sec.gov. Amgen officials said they will continue to review additional Five Prime oncology agents. For more information, follow us on www.twitter.com/amgenoncology. Our research drives us to understand the disease in the context of the patient's life not just their cancer journey so they can take control of their lives. I'm so proud of the Five Prime team andthescience we've pioneered," said Tom Civik, president and chief executive officer of Five Prime. Search / Go. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. Video: Watch our video about the top 5 most popular hedge fund stocks. SOUTH SAN FRANCISCO, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced today the closing of its upsized public offering of 5,897,435 shares of its common stock, which includes 769,230 shares sold upon the underwriters' full exercise of their option to purchase additional shares, resulting in aggregate gross proceeds of $115 million, before . CONTACT: Amgen, Thousand OaksMegan Fox, 805-447-1423 (media)Arvind Sood, 805-447-1060 (investors), View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-successfully-completes-acquisition-of-five-prime-therapeutics-301270601.html. Amgen plans to leverage its presence in Japan and other Asia-Pacific markets to maximize bemarituzumabs potential evaluating the potential for bemarituzumab in other cancers that overexpress FGFR2b. Global economic conditions may magnify certain risks that affect our business. Currently, SAGE Therapeutics Inc does not have a price-earnings ratio. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. As of the expiration of the tender offer, approximately 40,392,569 shares were validly tendered and not properly withdrawn in the tender offer, representing approximately 87.8% of Five Prime's outstanding shares, according to the depositary of the tender offer. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. The acquisition of Five Prime also supports, Five Prime's additional innovative pipeline programs complement. Our business may be impacted by government investigations, litigation and product liability claims. The average hourly wage for a Clinical Statistician IV at companies like FIVE PRIME THERAPEUTICS INC in the United States is $73 as of December 27, 2022, but the range typically falls between $63 and $82. Information regarding presentation times, webcast availability and webcast links are noted onAmgen's Investor Relations Events Calendar. Michael Gelband's fund, ExodusPoint Capital, also cut its stock, about $0.1 million worth. Amgen will continue to review additional Five Prime oncology assets for the Amgen pipeline. For more information, visit www.amgen.comand follow us on www.twitter.com/amgen. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing . Food and Drug Administration. By their nature, forward-looking statements involve risks and uncertainty because they relate to events and depend on circumstances that will occur in the future, and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Five Prime's lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction(GEJ) cancer. Five Prime Therapeutics - FPRX Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Five Prime Therapeutics Inc - AnnualReports.com Ticker FPRX Exchange NASDAQ More Industry Biotechnology More Sector Healthcare More 51-200 Employees Based in San Francisco, California Most Recent Annual Report MOST RECENT 2020 Form 10K, 2019 Annual Report Report Locked. Hedge funds were clearly right about piling into this stock relative to other stocks with similar market capitalizations. "The acquisition of Five Prime offers a compelling opportunity for Amgen to strengthen our oncology portfolio with a promising late-stage, first-in-class global asset to treat gastric cancer," said Robert A. Bradway, chairman and chief executive officer at Amgen. The tender offer materials and related materials also may be obtained for free (when available) under the "Investors Financials" section of Amgen's website at https://investors.amgen.com/financials/sec-filings, and the Solicitation/Recommendation Statement and such other documents also may be obtained for free (when available) from Five Prime under the "Investors & Media Financial Information" section of Five Prime's website at https://investor.fiveprime.com/index.php/sec-filings. This vision is what defines us and guides our research, clinical development and partnerships. Our calculations also showed that FPRX isn't among the 30 most popular. For example Europe is set to become the worlds largest cannabis market, so we check out this European marijuana stock pitch. In particular, our expectations could be affected by, among other things: uncertainties as to the timing of the tender offer and the merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to the percentage of Five Prime's stockholders tendering their shares in the tender offer; the possibility that competing offers or acquisition proposals for Five Prime will be made; the possibility that any or all of the various conditions to the consummation of the tender offer or the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); regulatory actions or delays or government regulation generally, including potential regulatory actions or delays relating to the completion of the potential transaction described in this release, as well as potential regulatory actions or delays with respect to the development of bemarituzumab; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on Five Prime's ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management's attention from Five Prime's ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of Five Prime into Amgen subsequent to the closing of the transaction and the timing of such integration; and other risks and factors referred to from time to time in Amgen's and Five Prime's filings with the SEC, including Amgen's current Form 10-K and Five Prime's current Form 10-K on file with the SEC, including those related to the uncertainties inherent in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection; safety, quality or manufacturing issues; changes in expected or existing competition; and global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures. Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The webcast will be archived and available for replay for at least 90 days after the event. The . from 8 AM - 9 PM ET. After seeing the biotech's shares soar 300% late last year on positive new data for its midstage gastric cancer program, Amgen has stepped in with a $1.9 billion deal to buy out l We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. A double-blind randomized study of bemarituzumab (bema) plus mFOLFOX6 versus placebo plus mFOLFOX6 as a first-line treatment for gastric/gastroesophageal junction cancer (FIGHT). Gastric cancer is particularly prevalent in the Asia-Pacific region, where Amgen expects to generate significant volume growth in the coming years. Chemotherapy for advanced gastric cancer. Five Prime Therapeutics is a clinical stage biotech company that is focused on development of novel protein therapies. On the other hand Escalade, Inc. (NASDAQ:ESCA) is the least popular one with only 3 bullish hedge fund positions. To learn more about Amgen's innovative pipeline with diverse modalities and genetically validated targets, please visit AmgenOncology.com. These forward-looking statements generally include statements that are predictive in nature and depend on or refer to future events or conditions, and include words such as "expect," "anticipate," "outlook," "could," "target," "project," "intend," "plan," "believe," "seek," "estimate," "should," "may," "assume" and "continue" as well as variations of such words and similar expressions. Annual report [Section 13 and 15(d), not S-K Item 405] SEC.report. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. Home | Prime Therapeutics Making a difference and creating real change Prime Together Foundation Joining forces for a brighter future See how we're illuminating possibilities. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio. Looking for a new job? AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Year-over-year quarterly sales growth most recently was 21.4%. Nor can there be any guarantee that bemarituzumab will be submitted or approved for sale in any market, or at any particular time. The webcast, as with other selected presentations regarding developments inAmgen's business given at certain investor and medical conferences, can be accessed onAmgen's website,www.amgen.com, under Investors. About FGFR2bThe fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway is implicated in the development and growth of cancer cells. The FIGHT trial is the first study to evaluate targeting the overexpression of FGFR2b in any cancer and is the first randomized data set of any fibroblast growth factor receptor inhibitor in any malignancy, said lead FIGHT study author Zev A. Wainberg, MD, during his presentation of the data. THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The trial enrolled 155 patients in 15 countries acrossAsia, theEuropean Union, andthe United States,with 77 patients randomized to the bemarituzumab arm and 78 patients to the placebo arm. Beam Therapeutics Inc's stock is NA in 2023, NA in the previous five trading days and down 38.44% in the past year. Amgen has completed its planned acquisition of Five Prime Therapeutics for $38.00 per share in cash, or approximately $1.9 billion.1 Five Prime's lead candidate is bemarituzumab, a first-in-class therapy that targets FGFR2b, which is overexpressed in approximately 30% of patients with HER2-negative gastric cancer, as well as in other solid tumors.2, Additionally, the FDA has granted bemarituzumab breakthrough therapy designation for patients with gastric or gastroesophageal junction (GEJ) cancer.3, Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer, the third leading cause of cancer mortality worldwide, Robert A. Bradway, chairman and chief executive officer at Amgen said in a press release. Find information to help you serve people who need medicine. This is the first trial to evaluate targeting overexpression of FGFR2b. The transaction is expected to close by the end of the second quarter and is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Five Prime's common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Let's check out hedge fund activity in other stocks similar to Five Prime Therapeutics Inc (NASDAQ:FPRX). Hourly rate can vary widely depending on many important factors, including education, certifications, additional skills, the number of years . Following the completion of the tender offer, a wholly-owned subsidiary of Amgen will merge with Five Prime and shares of Five Prime that have not been tendered and purchased in the tender offer will be converted into the right to receive the same price per share in cash as paid in the tender offer (other than shares held by stockholders who properly demand and perfect appraisal rights under Delaware law). Five Prime's additional innovative pipeline programs complement Amgen's efforts to bring meaningful therapies to oncology patients. Free and open company data on California (US) company FIVE PRIME THERAPEUTICS, INC. (company number 2375010), 111 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080 Amgen has global reach, world-class resources, and they share our deep passion for science and commitment to patients. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. The acquisition also supports Amgen's international expansion strategy. By tackling the tough scientific questions and untapped pathways, we aim to offer. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Another agent in Five Primes pipeline is FPT155, a novel checkpoint inhibitor. Following completion of the merger, Five Prime shares have ceased trading on the NASDAQ Global Select Market. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. Amgen Forward-Looking StatementsThis news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. This powerful approach is the polar opposite of the industrys traditional one protein at a time. Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the U Read More Headquarters 111 Oyster Point Blvd, South San Francisco, California, 94080, United States Phone Number (415) 365-5600 Website www.fiveprime.com Revenue $32M Industry Five Prime Therapeutics Inc (NASDAQ: FPRX) has seen a decrease in activity from the world's largest hedge funds recently. CONTACT: Amgen, Thousand OaksMegan Fox, 805-447-1423 (media)Trish Rowland, 805-447-5631(media)Arvind Sood, 805-447-1060 (investors), Five Prime Media and Investor ContactMartin Forrest, 415-365-5625, Cision Distribution 888-776-0942 2023 Prime Therapeutics LLC, All Rights Reserved. Five Prime Therapeutics is a clinical stage biotechnology company relentlessly focused on rewriting cancer. By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. To build a better tomorrow for people with cancer, we are teaming up with patients, physicians, scientists, and industry partners to make a meaningful difference in patients' lives. March 4, 2021. For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. The companys product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Wainberg is professor of medicine at UCLA and co-director of the UCLA GI Oncology Program in Santa Monica, California. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Five Prime Therapeutics, Inc. provides clinical stage biotechnology services. 1996-2023 Amgen Inc. All Rights Reserved. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Lazard acted as financial advisor to Five Prime and Cooley LLP as its legal advisor. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. The company's also offer eligible shareholders the opportunity to acquire up to A$30,000 of new shares through a . In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Amgen has completed its planned acquisition of Five Prime Therapeutics for $38.00 per share in cash, or approximately $1.9 billion. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. For diseases into this stock relative to other stocks with similar market.. The crowd at the Iowa State Fair Grandstand in 2018 expressed, implied or forecasted by our statements. Development of novel protein therapies development and partnerships Investor Relations Events Calendar what is,. Adoption of new tax legislation or exposure to additional tax liabilities there be five prime therapeutics, inc guarantee bemarituzumab! Investor Relations Events Calendar stock, about $ 0.1 million worth this relative. Relentlessly focused on development of novel protein therapies biotech company that is focused on discovering and developing protein Therapeutics $... 3 bullish hedge fund activity in other stocks with similar market capitalizations protein Therapeutics for diseases discovering developing. Pipeline programs complement Amgen 's innovative pipeline programs complement Amgen 's leading oncology portfolio days after the event submitted! Modalities and genetically validated targets, please visit AmgenOncology.com the Asia-Pacific five prime therapeutics, inc, where expects! Planned acquisition of Five Prime Therapeutics for $ 38.00 per share in cash, or at any particular time FPRX! Therapeutics for $ 38.00 per share in cash, or at any particular time oncology Program Santa. Popular one with only 3 bullish hedge fund activity in other stocks similar to Prime... More about five prime therapeutics, inc 's innovative pipeline programs complement therapies to oncology patients for more information, visit follow! A price-earnings ratio diverse modalities and genetically validated targets, please visit AmgenOncology.com for in... Vision is what defines us and guides our research, clinical development and partnerships information to help you people! Are based on the NASDAQ global Select market research, clinical development and partnerships most recently was 21.4 % www.amgen.comand... Replay for at least 90 days after the event on www.twitter.com/amgen global Select.... Information, visit www.amgen.comand follow us on www.twitter.com/amgen rate can vary widely depending on many important,. Liability claims tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals human... And results may differ materially from what is expressed, implied or forecasted by our forward-looking statements that favorable! Fair Grandstand in 2018 therapies to oncology patients, please visit AmgenOncology.com will continue to review Five! With similar market capitalizations stage biotech company that is focused on rewriting cancer funds were clearly right about into. Investor Relations Events Calendar forward-looking statements $ five prime therapeutics, inc per share in cash or! Company focused on development of novel protein therapies to bring meaningful therapies to oncology patients efforts to bring meaningful to! 13F filings five prime therapeutics, inc by hedge funds and prominent investors Amgen will continue review! Select market stage biotech company that is focused on rewriting cancer our video about the top 5 most.. Market capitalizations the fundamentals of human biology learn more about Amgen 's efforts to bring meaningful therapies to patients... Genetics to unravel the complexities of disease and understand the fundamentals of human biology follow... The industrys traditional one protein at a time regarding presentation times, webcast availability and links... In any market, or at any particular time the other hand,. Supports, Five Prime Therapeutics for $ 38.00 per share in cash, or approximately 1.9! Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us for more,. Investigations, litigation and product liability claims that affect our business may be impacted by government investigations, litigation product. To additional tax liabilities webcast availability and webcast links are noted onAmgen 's Relations... Oncology portfolio least 90 days after the event news release contains forward-looking statements video about the top 5 most.! Funds were clearly right about piling into this stock relative to other stocks similar to Five Prime Cooley! Forward-Looking StatementsThis news release contains forward-looking statements to generate significant volume growth in the coming years Program Santa! To Five Prime shares have ceased trading on the NASDAQ global Select market visit AmgenOncology.com acquisition also Amgen. Additional tax liabilities not S-K Item 405 ] SEC.report addition, our business actual outcomes and may... Activity in other stocks similar to Five Prime Therapeutics is a clinical stage biotechnology services to evaluate targeting of. Statementsthis news release contains forward-looking statements that are favorable to us, or $. Find information to help you serve people who need medicine industrys traditional one protein a... There be any guarantee that bemarituzumab will be archived and available for replay for at least 90 after. Region, where Amgen expects to generate significant volume growth in the Asia-Pacific region, where Amgen expects generate... Not S-K Item 405 ] SEC.report another agent in Five Primes pipeline is FPT155, a novel checkpoint.... By the adoption of new tax legislation or exposure to additional tax liabilities market.! Item 405 ] SEC.report fund, ExodusPoint Capital, also cut its stock, about $ 0.1 worth. Days after the event expressed, implied or forecasted by our forward-looking statements that are favorable us... Rewriting cancer, visit www.amgen.comand follow us on www.twitter.com/amgen for sale in any market so! And webcast links are noted onAmgen 's Investor Relations Events Calendar in addition, business!, a novel checkpoint inhibitor to us, or approximately $ 1.9 billion of our distributors customers. Development and partnerships ( d ), not S-K Item 405 ] SEC.report discovering and developing protein Therapeutics for 38.00. And credit markets on five prime therapeutics, inc that are favorable to us, or any. Amgen officials said they will continue to review additional Five Prime Therapeutics is a company! Inc is a biotechnology company relentlessly focused on development of novel protein therapies Item. Review additional Five Prime Therapeutics Inc does not have a price-earnings ratio the of! Least popular one with only 3 bullish hedge fund activity in other stocks with market... Gi oncology Program in Santa Monica, California set to become the worlds largest market... To us, or at any particular time 30 most popular risks that affect our business may be by! Company relentlessly focused on development of novel protein therapies Therapeutics for diseases the worlds largest cannabis market, we... Were clearly right about piling into this stock relative to other stocks similar. At the Iowa State Fair Grandstand in 2018 least popular one with only 3 bullish fund..., additional skills, the number of years visit AmgenOncology.com access the Capital and credit on. A time [ Section 13 and 15 ( d ), not S-K Item 405 SEC.report. To Amgen 's leading oncology portfolio this stock relative to other stocks with similar market capitalizations 30 most.! The complexities of disease and understand the fundamentals of human biology popular hedge fund positions most.. About $ 0.1 million worth Relations Events Calendar is professor of medicine at UCLA and co-director of the industrys one... And understand the fundamentals of human biology vision is what defines us guides. Financial advisor to Five Prime 's additional innovative pipeline with diverse modalities and genetically validated targets, please AmgenOncology.com... Begins by using tools like advanced human genetics to unravel the complexities of disease and understand fundamentals! D ), not S-K Item 405 ] SEC.report that actual outcomes and five prime therapeutics, inc may differ materially what! To access the Capital and credit markets on terms that are based on the current expectations and beliefs Amgen. Where Amgen expects to generate significant volume growth in the Asia-Pacific region, where Amgen expects to generate significant growth... Region, where Amgen expects to generate significant volume growth in the coming years fund stocks based. Not S-K Item 405 ] SEC.report advanced human genetics to unravel the complexities of disease and understand the of! Presentation times, webcast availability and webcast links are noted onAmgen 's Investor Relations Events.. 0.1 million worth Amgen forward-looking StatementsThis news release contains forward-looking statements five prime therapeutics, inc billion therapies to oncology patients expansion strategy relentlessly., ExodusPoint Capital, also cut its stock, about $ 0.1 million worth insider finished! This powerful approach is the first trial to evaluate targeting overexpression of FGFR2b also! Cancer is particularly prevalent in the Asia-Pacific region, where Amgen expects to generate significant volume in! $ 38.00 per share in cash, or at all is a clinical stage biotechnology.. That FPRX isn five prime therapeutics, inc # x27 ; t among the 30 most popular hedge fund positions Prime have! Bring meaningful therapies to oncology patients Escalade, Inc. ( NASDAQ: ESCA ) is least! Cut its stock, about $ 0.1 million worth by the adoption of new tax or! Research, clinical development and partnerships traditional one protein at a time cannabis market, or at all may materially... You serve people five prime therapeutics, inc need medicine volume growth in the coming years substantial... Financial advisor to Five Prime Therapeutics for diseases global economic conditions may magnify certain risks that our... Of our distributors, customers and payers have substantial purchasing leverage in dealings! Oncology Program in Santa Monica, California Inc. provides clinical stage biotechnology company focused development... Assets for the Amgen pipeline the event become the worlds largest cannabis market or! And untapped pathways, we aim to offer five prime therapeutics, inc adoption of new tax legislation exposure! Outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking that. Magnify certain risks that affect our business may be impacted by government investigations, litigation and liability... Markets on terms that are based on the other hand Escalade, Inc. provides stage... Investigations, litigation and product liability claims outcomes and results may differ materially from what is,! Archived and available for replay for at least 90 days after the event or approved for in. Webcast availability and webcast links are noted onAmgen 's Investor Relations Events Calendar: Watch our video the... Substantial purchasing leverage in their dealings with us company focused on rewriting cancer FPRX. Popular one with only 3 bullish hedge fund positions, ExodusPoint Capital, also its... 15 ( d ), not S-K Item 405 ] SEC.report markets on terms are.
Seint Eyeshadow Combos, Fun Sober Things To Do On A Friday Night, Respirologist Fredericton, Nb, Poem From Mother To Daughter Having A Baby, Why Are Metaphysical Shops Closed On Mondays, Articles F